视神经疾病药物市场－全球产业规模、份额、趋势、机会和预测（按处方类型、按治疗学、按最终用户、按地区和竞争细分，2020-2030 年）

2024 年全球视光学障碍药物市场价值为 376.8 亿美元，预计到 2030 年将达到 603.5 亿美元，预测期内年复合成长率(CAGR) 为 8.14%。视觉疾病，也称为眼科疾病或眼部疾病，涵盖影响眼睛和视觉系统的一系列疾病。这些疾病会损害眼睛结构或功能，导致视力障碍、不适或其他症状。它们可以影响各个年龄层的人，严重程度从轻微到严重不等。

眼部疾病的治疗方案多种多样，取决于病情的性质和进展。介入措施可能包括矫正镜片（眼镜或隐形眼镜）、药物治疗（眼药水或口服药物）、外科手术、改变生活方式以及旨在早期发现和持续监测的常规眼科检查。这些治疗的首要目标是保持视觉功能并维持整体眼部健康。

关键市场驱动因素

技术进步

主要市场挑战

通用竞争

主要市场趋势

以患者为中心的治疗方法

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球视光障碍药物市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依处方类型（非处方药、处方眼科药）
  • 依治疗学分类（老年性黄斑部病变、结膜炎、糖尿病黄斑水肿、糖尿病视网膜病变、干眼症、眼癌、青光眼等）
  • 按最终使用者（诊断中心、眼科诊所、医院）
  • 按公司分类（2024）
• 市场地图

第六章：亚太地区视光障碍药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第七章：欧洲视光障碍药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 西班牙
  • 义大利
  • 英国

第八章：北美视光障碍药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第九章：南美洲视神经疾病药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲视光障碍药物市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章：全球视神经疾病药物市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章： 大环境分析

第 16 章：竞争格局

• Alcon Inc.
• Novartis ag
• Johnson & Johnson services, Inc.
• Bausch health
• Merck & co. Inc.
• Coherus biosciences, Inc.
• Allergan
• Pfizer, Inc.
• Bayer ag
• Santen pharmaceuticals co. Ltd.
• Genetech, Inc.

第 17 章：策略建议

第18章调查会社について・免责事项

Global Optical Disorders Drugs Market for optical disorders drugs was valued at USD 37.68 billion in 2024 and is projected to reach USD 60.35 billion by 2030, expanding at a compound annual growth rate (CAGR) of 8.14% during the forecast period. Optical disorders, also referred to as ophthalmic or eye disorders, encompass a broad spectrum of conditions affecting the eyes and the visual system. These disorders can impair the structure or function of ocular components, leading to visual disturbances, discomfort, or additional symptoms. They can affect individuals across all age groups and vary in severity from mild to debilitating.

Treatment options for optical disorders are diverse and depend on the nature and progression of the condition. Interventions may include corrective lenses (eyeglasses or contact lenses), pharmacological therapies (eye drops or oral medications), surgical procedures, lifestyle changes, and routine eye examinations aimed at early detection and ongoing monitoring. The overarching goal of these treatments is to preserve visual function and maintain overall ocular health.

Key Market Drivers

Technological Advancements

Recent technological progress in ophthalmology has significantly shaped the pharmaceutical landscape. One major development is the introduction of sustained-release drug delivery systems that provide controlled and extended medication release, reducing the frequency of administration. A notable example is Roche's Susvimo (ranibizumab injection), which received FDA approval in February 2025 for the treatment of diabetic macular edema (DME). It is the first and only FDA-approved therapy shown to maintain vision in DME patients with fewer treatments compared to standard care.

Nanotechnology is playing a critical role in enhancing ocular drug delivery. Nanogels and other nano-sized carriers have demonstrated improved tissue penetration and bioavailability, particularly in treating anterior segment conditions such as glaucoma, cataracts, dry eye syndrome, and bacterial keratitis.

Advancements in topical ophthalmic formulations are also contributing to market growth. For example, lipid-based eye drops have been developed to effectively manage evaporative dry eye disease by stabilizing the tear film and reducing tear evaporation.

Biotechnology has facilitated the emergence of gene therapies that target specific molecular pathways involved in various ocular diseases. These therapies have shown potential in delivering long-term visual improvements for patients suffering from inherited or degenerative retinal conditions.

Key Market Challenges

Generic Competition

The growing presence of generic drugs poses a significant challenge for brand-name pharmaceutical companies operating in the optical disorders segment. Once patent protections expire, lower-cost generics enter the market, often at substantially reduced prices, impacting revenue streams of original drug manufacturers. Patients and healthcare providers frequently opt for generics due to their affordability, leading to decreased market share for innovator products.

The rapid adoption of generics can lead to price erosion and force originator companies to reduce prices or offer discounts to maintain competitiveness. This shift adversely affects profit margins and limits the ability to reinvest in research and development (R&D). Moreover, the loss of exclusivity following patent expiry often results in diminished market dominance.

This competitive pressure can discourage pharmaceutical firms from pursuing new drug innovations in the ophthalmic space, given the reduced commercial incentives once generics become viable. As a result, companies must carefully balance R&D investments with strategic planning to mitigate the risks associated with generic competition.

Key Market Trends

Patient-Centric Treatment Approaches

There is a growing trend toward tailoring ophthalmic treatment plans to align with individual patient preferences and lifestyles. Healthcare providers are increasingly considering factors such as daily routines, treatment goals, and comfort when selecting medications and therapeutic approaches.

Patients express varied preferences for modes of drug administration-some favor eye drops, while others may opt for ointments or less frequent dosing schedules. In response, pharmaceutical companies are expanding their product portfolios to include a range of delivery formats designed for ease of use and integration into daily life.

User-friendly packaging and intuitive application mechanisms are being developed to improve adherence to treatment protocols. Additionally, reducing the occurrence of side effects is a major focus in drug development, as improved tolerability leads to higher compliance and better clinical outcomes.

Flexibility in dosing is also highly valued by patients. Drugs offering once-daily or extended dosing intervals provide greater convenience and enhance patient autonomy. The industry is further shifting toward collaborative care models, emphasizing patient education and shared decision-making between patients and healthcare providers. This approach ensures that treatment plans reflect individual values and objectives, leading to increased satisfaction and better management of eye disorders.

Key Market Players

• Alcon Inc.
• Novartis ag
• Johnson & Johnson services, Inc.
• Bausch health
• Merck & co. Inc.
• Coherus biosciences, Inc.
• Allergan
• Pfizer, Inc.
• Bayer ag
• Santen pharmaceuticals co. Ltd.
• Genetech, Inc.

Report Scope:

In this report, the Global Optical Disorders Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Optical Disorders Drugs Market, By Prescription Type:

• Over-The-Counter Drugs
• Prescription Ophthalmic Drugs

Optical Disorders Drugs Market, By Therapeutics:

• Age-Related Macular Degeneration
• Conjunctivitis
• Diabetic Macular Edema
• Diabetic Retinopathy
• Dry Eye
• Eye Cancer
• Glaucoma
• Others

Optical Disorders Drugs Market, By End User:

• Diagnostic Centers
• Eye Clinics
• Hospitals

Optical Disorders Drugs Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Optical Disorders Drugs Market.

Available Customizations:

Global Optical Disorders Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Optical Disorders Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Prescription Type (Over-The-Counter Drugs, Prescription Ophthalmic Drugs)
  • 5.2.2. By Therapeutics (Age-Related Macular Degeneration, Conjunctivitis, Diabetic Macular Edema, Diabetic Retinopathy, Dry Eye, Eye Cancer, Glaucoma, others)
  • 5.2.3. By End User (Diagnostic Centers, Eye Clinics, Hospitals)
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Optical Disorders Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Prescription Type
  • 6.2.2. By Therapeutics
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Optical Disorders Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Prescription Type
      • 6.3.1.2.2. By Therapeutics
      • 6.3.1.2.3. By End User
  • 6.3.2. India Optical Disorders Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Prescription Type
      • 6.3.2.2.2. By Therapeutics
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Optical Disorders Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Prescription Type
      • 6.3.3.2.2. By Therapeutics
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Optical Disorders Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Prescription Type
      • 6.3.4.2.2. By Therapeutics
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Optical Disorders Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Prescription Type
      • 6.3.5.2.2. By Therapeutics
      • 6.3.5.2.3. By End User

7. Europe Optical Disorders Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Prescription Type
  • 7.2.2. By Therapeutics
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Optical Disorders Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Prescription Type
      • 7.3.1.2.2. By Therapeutics
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Optical Disorders Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Prescription Type
      • 7.3.2.2.2. By Therapeutics
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Optical Disorders Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Prescription Type
      • 7.3.3.2.2. By Therapeutics
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Optical Disorders Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Prescription Type
      • 7.3.4.2.2. By Therapeutics
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Optical Disorders Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Prescription Type
      • 7.3.5.2.2. By Therapeutics
      • 7.3.5.2.3. By End User

8. North America Optical Disorders Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Prescription Type
  • 8.2.2. By Therapeutics
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Optical Disorders Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Prescription Type
      • 8.3.1.2.2. By Therapeutics
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Optical Disorders Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Prescription Type
      • 8.3.2.2.2. By Therapeutics
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Optical Disorders Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Prescription Type
      • 8.3.3.2.2. By Therapeutics
      • 8.3.3.2.3. By End User

9. South America Optical Disorders Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Prescription Type
  • 9.2.2. By Therapeutics
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Optical Disorders Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Prescription Type
      • 9.3.1.2.2. By Therapeutics
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Optical Disorders Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Prescription Type
      • 9.3.2.2.2. By Therapeutics
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Optical Disorders Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Prescription Type
      • 9.3.3.2.2. By Therapeutics
      • 9.3.3.2.3. By End User

10. Middle East and Africa Optical Disorders Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Prescription Type
  • 10.2.2. By Therapeutics
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Optical Disorders Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Prescription Type
      • 10.3.1.2.2. By Therapeutics
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Optical Disorders Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Prescription Type
      • 10.3.2.2.2. By Therapeutics
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Optical Disorders Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Prescription Type
      • 10.3.3.2.2. By Therapeutics
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Optical Disorders Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Alcon Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Novartis ag
• 16.3. Johnson & Johnson services, Inc.
• 16.4. Bausch health
• 16.5. Merck & co. Inc.
• 16.6. Coherus biosciences, Inc.
• 16.7. Allergan
• 16.8. Pfizer, Inc.
• 16.9. Bayer ag
• 16.10. Santen pharmaceuticals co. Ltd.
• 16.11. Genetech, Inc.

17. Strategic Recommendations

18. About Us & Disclaimer